Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model

• Published in: Doklady. Biochemistry and biophysics Vol. 478; no. 1; pp. 30 - 33
• Main Authors: Shchelkunov, S. N., Razumov, I. A., Kolosova, I. V., Romashchenko, A. V., Zavjalov, E. L.
• Format: Journal Article
• Language: English
• Published: Moscow Pleiades Publishing 2018; Springer Nature B.V
• Subjects: Animals; Biochemistry; Biological and Medical Physics; Biomedical and Life Sciences; Biophysics; Brain cancer; Brain tumors; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Glioblastoma; Glioblastoma - pathology; Glioblastoma - therapy; Glioblastoma - virology; Humans; Immunotherapy; Injection; Intravenous administration; Laboratory animals; Life Sciences; Lysis; Mice; Mice, SCID; Molecular Biology; Oncolysis; Oncolytic Virotherapy; Rodents; Thymidine; Thymidine kinase; Tumor Burden; Tumorigenesis; Viruses; Xenografts
• ISSN: 1607-6729; 1608-3091
• DOI: 10.1134/S1607672918010088

The possibility of glioblastoma virotherapy at intravenous injection of the LIVP–GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP–GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP–GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.